FindMyKOL
Clinical trialNCT02326584CompletedPhase 1Interventional

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

SponsorSeagen Inc.Enrollment116Acute Myelogenous LeukemiaAcute Myeloid Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself (monotherapy) or in combination with other standard treatments. The main purpose of this study is to find the best dose and schedule for SGN-CD33A when given in combination with standard induction treatment, in combination with standard consolidation treatment, or by itself for maintenance treatment. This will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

  • City of Hope National Medical Center

    Duarte, California, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, United States

  • Cardinal Bernardin Cancer Center / Loyola University Medical Center

    Maywood, Illinois, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Karmanos Cancer Institute / Wayne State University

    Detroit, Michigan, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, United States

  • Cleveland Clinic, the

    Cleveland, Ohio, United States

  • James Cancer Hospital / Ohio State University

    Columbus, Ohio, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

  • Charles A. Sammons Cancer Center / Baylor University Medical Center

    Dallas, Texas, United States

  • Md Anderson Cancer Center / University of Texas

    Houston, Texas, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Daunorubicin →High dose cytarabine for consolidationSGN-CD33AStandard dose cytarabine for induction
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2014
Primary completion
30 Jan 2017
Completion
10 Apr 2018
Last update posted
9 May 2018
Registered enrollment
116
Registry id
NCT02326584
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.